NCT00000887View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 2004

Conditions
HIV InfectionsPregnancy
Interventions
DRUG

Nelfinavir mesylate

DRUG

Lamivudine

DRUG

Zidovudine

Trial Locations (7)

27710

UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill

70112

Tulane/LSU Maternal/Child CRS, New Orleans

90033

Usc La Nichd Crs, Los Angeles

191341095

St. Christopher's Hosp. for Children, Philadelphia

212874933

Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore

701122699

Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans

021155724

HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000887 - A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants | Biotech Hunter | Biotech Hunter